Table 5.
Inflammatory and anti-inflammatory markers in asymptomatic subjects before and after intervention.
| CRP (μg/L) | Adiponectin (μg/mL) | Bilirubin (μmol/L) | UA (μmol/L) | |||||
|---|---|---|---|---|---|---|---|---|
| Placebo | Royal jelly | Placebo | Royal jelly | Placebo | Royal jelly | Placebo | Royal jelly | |
| Initial | 1.25±0.54 | 1.59±0.66 | 12.0±6.3 | 12.8±5.8 | 12.0±5.3 | 7.8±4.5c | 346±76 | 294±84 |
| Week 4 | 1.37±0.83 | 1.36±0.52 | 11.8±6.4 | 13.6±6.4 | 9.2±4.9b | 9.6±5.0a, b | 293±69b | 293±60a |
| Week 8 | 1.32±0.76 | 1.28±0.42a, b | 8.9±6.5 | 17.2±6.7 a, b, c | 9.4±6.0b | 10.5±5.2a, b | 302±53b | 310±74a |
| F/U | 1.48±0.73 | 1.25±0.31a, b | 8.5±5.1 | 16.7±6.8a, b, c | 8.0±4.3b | 8.2±4.7a | 320±70 | 316±57a |
Abbreviation: CRP, C-reactive protein; F/U, follow up; UA, uric acid.
Values are expressed as means ± SD.
a p-value denotes significant (p<0.05) difference between the change from baseline on royal jelly vs. placebo.
b p-value denotes significant (p<0.05) difference as compared with the initial within group using a paired t-test.
c p-value denotes significant (p<0.05) difference between the two groups (royal jelly vs. placebo) at a given time point.